Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 11.652
Filter
2.
PLoS One ; 19(5): e0302716, 2024.
Article in English | MEDLINE | ID: mdl-38701097

ABSTRACT

OBJECTIVE: We conducted a systematic evaluation of the therapeutic efficacy and complications of tolterodine and α-adrenergic receptor blockers in alleviating ureteral stent-related symptoms. METHODS: Until August 2023, we conducted a comprehensive literature search on PubMed, Embase, Web of Science, and Cochrane Library to identify randomized controlled trials evaluating the efficacy and complications of tolterodine and α-adrenergic receptor blockers in treating ureteral stent-related symptoms. Two reviewers independently screened studies and extracted data. The scores from various domains of the Ureteral Stent Symptom Questionnaire (USSQ) were summarized and compared, and statistical analysis was performed using RevMan 5.4.0 software. RESULTS: A total of 8 studies met the inclusion criteria for our analysis. These studies were conducted at different centers. All studies were randomized controlled trials, involving a total of 487 patients, with 244 patients receiving α-adrenergic receptor blockers and 243 patients receiving tolterodine. The results showed that tolterodine demonstrated significantly better improvement in body pain (MD, 1.56; 95% CI [0.46, 2.66]; p = 0.005) (MD, 0.46; 95% CI [0.12, 0.80]; p = 0.008) (MD, 3.21; 95% CI [1.89, 4.52]; p = 0.00001) among patients after ureteral stent placement compared to α-adrenergic receptor blockers at different time points. Additionally, at 4 weeks, tolterodine showed superior improvement in general health (MD, 0.15; 95% CI [0.03, 0.27]; p = 0.01) and urinary symptoms (MD, 1.62; 95% CI [0.59, 2.66]; p = 0.002) compared to α-adrenergic receptor blockers, while at 6 weeks, tolterodine showed better improvement in work performance (MD, -1.60; 95% CI [-2.73, -0.48]; p = 0.005) compared to α-adrenergic receptor blockers. Additionally, the incidence of dry mouth (RR, 4.21; 95% CI [1.38, 12.87]; p = 0.01) is higher with the use of tolterodine compared to α-adrenergic receptor blockers. However, there were no significant statistical differences between the two drugs in other outcomes. CONCLUSION: This meta-analysis suggests that tolterodine is superior to α-adrenergic receptor blockers in improving physical pain symptoms after ureteral stent placement, while α-adrenergic receptor blockers are more effective than tolterodine in enhancing work performance. Additionally, the incidence of dry mouth is higher with the use of tolterodine compared to α-adrenergic receptor blockers. However, higher-quality randomized controlled trials are needed to further investigate this issue.


Subject(s)
Adrenergic alpha-Antagonists , Stents , Tolterodine Tartrate , Ureter , Tolterodine Tartrate/therapeutic use , Humans , Stents/adverse effects , Adrenergic alpha-Antagonists/therapeutic use , Ureter/surgery , Randomized Controlled Trials as Topic , Treatment Outcome
3.
Eur Rev Med Pharmacol Sci ; 28(8): 3263-3267, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38708484

ABSTRACT

OBJECTIVE: To determine whether there is a relationship between carotid artery stenosis percentage and complications. PATIENTS AND METHODS: The study included 109 patients treated with carotid artery stenting in our center. The indication for stenting was accepted as carotid artery stenosis above 50% in symptomatic patients and over 70% in asymptomatic patients. Complications were compared between groups with <90% and ≥90% stenosis. RESULTS: There was no procedure-related mortality in any of the patients. Minor complications developed in 22 patients (20.2%). Prolonged hypotension/bradycardia occurred in 17 patients (77.3%), and a transient ischemic attack in five (22.7%). Inguinal access complications were detected in three patients (2.7%). Major complications developed in 11 patients (10%), of whom five (45.4%) had hyperperfusion syndrome, five (45.4%) had microinfarcts, and one (9%) had acute stent thrombosis. No significant difference was observed in age, gender, major and minor complications, or inguinal access site complications between the patients with <90% and ≥90% stenosis. There was also no statistically significant difference in complications according to the open or closed cell morphology of the selected stent. CONCLUSIONS: The most important result of our study is that there was no significant difference in complications between the patients who underwent carotid stenting due to <90% and ≥90% stenosis.


Subject(s)
Carotid Stenosis , Stents , Humans , Carotid Stenosis/surgery , Stents/adverse effects , Male , Female , Aged , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Ischemic Attack, Transient/etiology
4.
Neurol India ; 72(2): 408-410, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38691486

ABSTRACT

Acute glaucoma following carotid artery recanalization is a rare but severe complication of underlying ocular ischemic syndrome. We present a case of a 71-year-old woman with ocular ischemic syndrome and severe stenosis of the right internal and external carotid artery undergoing carotid artery stenting. Immediate postprocedural angiography showed pronounced reperfusion of the ophthalmic artery. Subsequently, the patient developed vision-threatening acute glaucoma despite treatment with acetazolamide. Monitoring of intraocular pressure is important in patients who are at risk of developing ocular ischemic syndrome because of internal carotid artery stenosis. Interventionalists should also assess the degree of vascular collateralization from the external carotid artery.


Subject(s)
Carotid Artery, Internal , Carotid Stenosis , Glaucoma , Stents , Humans , Female , Aged , Carotid Stenosis/surgery , Stents/adverse effects , Glaucoma/etiology , Glaucoma/surgery , Carotid Artery, Internal/diagnostic imaging , Ischemia/etiology
5.
Biomacromolecules ; 25(5): 3098-3111, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38606583

ABSTRACT

Biodegradable stents are the most promising alternatives for the treatment of cardiovascular disease nowadays, and the strategy of preparing functional coatings on the surface is highly anticipated for addressing adverse effects such as in-stent restenosis and stent thrombosis. Yet, inadequate mechanical stability and biomultifunctionality limit their clinical application. In this study, we developed a multicross-linking hydrogel on the polylactic acid substrates by dip coating that boasts impressive antithrombotic ability, antibacterial capability, mechanical stability, and self-healing ability. Gelatin methacryloyl, carboxymethyl chitosan, and oxidized sodium alginate construct a double-cross-linking hydrogel through the dynamic Schiff base chemical and in situ blue initiation reaction. Inspired by the adhesion mechanism employed by mussels, a triple-cross-linked hydrogel is formed with the addition of tannic acid to increase the adhesion and antibiofouling properties. The strength and hydrophilicity of hydrogel coating are regulated by changing the composition ratio and cross-linking degree. It has been demonstrated in tests in vitro that the hydrogel coating significantly reduces the adhesion of proteins, MC3T3-E1 cells, platelets, and bacteria by 85% and minimizes the formation of blood clots. The hydrogel coating also exhibits excellent antimicrobial in vitro and antiinflammatory properties in vivo, indicating its potential value in vascular intervention and other biomedical fields.


Subject(s)
Anti-Inflammatory Agents , Anticoagulants , Bivalvia , Polyesters , Stents , Animals , Bivalvia/chemistry , Mice , Polyesters/chemistry , Polyesters/pharmacology , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Stents/adverse effects , Anticoagulants/chemistry , Anticoagulants/pharmacology , Gelatin/chemistry , Hydrogels/chemistry , Hydrogels/pharmacology , Chitosan/chemistry , Chitosan/analogs & derivatives , Chitosan/pharmacology , Alginates/chemistry , Alginates/pharmacology , Coated Materials, Biocompatible/chemistry , Coated Materials, Biocompatible/pharmacology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Tannins/chemistry , Tannins/pharmacology , Humans , Methacrylates
6.
Eur J Cardiothorac Surg ; 65(5)2024 May 03.
Article in English | MEDLINE | ID: mdl-38569918

ABSTRACT

OBJECTIVES: Our goal was to access early and mid-term outcomes of a gutter-plugging chimney stent graft for treatment of Stanford type B aortic dissections in the clinical trial Prospective Study for Aortic Arch Therapy with stENt-graft for Chimney technology (PATENCY). METHODS: Between October 2018 and March 2022, patients with Stanford type B aortic dissections were treated with the Longuette chimney stent graft in 26 vascular centres. The efficiency and the incidence of adverse events over 12 months were investigated. RESULTS: A total of 150 patients were included. The technical success rate was 99.33% (149/150). The incidence of immediate postoperative endoleak was 5.33% (8/150, type I, n = 6; type II, n = 1; type IV, n = 1) neurologic complications (stroke or spinal cord ischaemia); the 30-day mortality was 0.67% (1/150) and 1.33% (2/150), respectively. During the follow-up period, the median follow-up time was 11.67 (5-16) months. The patent rate of the Longuette graft was 97.87%. Two patients with type I endoleak underwent reintervention. The follow-up rate of the incidence of retrograde A type aortic dissection was 0.67% (1/150). There was no paraplegia, left arm ischaemia or stent migration. CONCLUSIONS: For revascularization of the left subclavian artery, the Longuette chimney stent graft can provide an easily manipulated, safe and effective endovascular treatment. It should be considered a more efficient technique to prevent type Ia endoleak. Longer follow-up and a larger cohort are needed to validate these results. CLINICAL TRIAL REGISTRY NUMBER: NCT03767777.


Subject(s)
Aortic Aneurysm, Thoracic , Aortic Dissection , Blood Vessel Prosthesis Implantation , Blood Vessel Prosthesis , Endovascular Procedures , Stents , Adult , Aged , Female , Humans , Male , Middle Aged , Aortic Aneurysm, Thoracic/surgery , Aortic Dissection/surgery , Blood Vessel Prosthesis Implantation/adverse effects , Blood Vessel Prosthesis Implantation/methods , Blood Vessel Prosthesis Implantation/instrumentation , Endovascular Procedures/methods , Endovascular Procedures/adverse effects , Endovascular Procedures/instrumentation , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Prospective Studies , Prosthesis Design , Stents/adverse effects , Treatment Outcome , Case-Control Studies
7.
Medicine (Baltimore) ; 103(16): e37765, 2024 Apr 19.
Article in English | MEDLINE | ID: mdl-38640312

ABSTRACT

The objective was to evaluate the incidence and degree of double-J ureteral stent (DJUS) migration. Additionally, we aimed to investigate the risk factors associated with stent migration in the orthotopic neobladder group. In this retrospective study, 61 consecutive patients were included; 35 patients (45 DJUS placements) underwent radical cystectomy with orthotopic neobladder and 26 patients (35 DJUS placements) underwent urinary bladder without cystectomy between July 2021 and March 2023. All the patients were treated with a DJUS for ureteric strictures. The technical success rate was 100% in each group. The DJUS migration was significantly higher in the orthotopic neobladder group, with 22 of 45 cases (48.9%), compared to the urinary bladder group, which had 4 of 35 cases (11.4%) (P ≤ .001). Among the patients in the orthotopic neobladder group who experienced DJUS migration, stent dysfunction occurred in 18 cases (81.8%), which was statistically significant (P = .003). Multivariate logistic regression analysis revealed that only the size of the DJUS was significantly and positively associated with migration (odds ratio:10.214, P = .010). DJUS migration can easily occur in patients undergoing radical cystectomy and orthotopic neobladder, and smaller stent sizes are associated with a higher incidence of migration.


Subject(s)
Urinary Bladder Neoplasms , Urinary Diversion , Humans , Cystectomy/adverse effects , Urinary Bladder/surgery , Urinary Diversion/adverse effects , Retrospective Studies , Constriction, Pathologic/surgery , Urinary Bladder Neoplasms/surgery , Urinary Bladder Neoplasms/etiology , Risk Factors , Stents/adverse effects , Anastomosis, Surgical/adverse effects , Ileum/surgery
8.
J Investig Med High Impact Case Rep ; 12: 23247096241238527, 2024.
Article in English | MEDLINE | ID: mdl-38646799

ABSTRACT

Biliary endoprostheses are widely used in the treatment of biliary lithiasis, malignant and benign strictures, and occasionally in long-lasting biliary fistulas. They can be placed endoscopically during endoscopic retrograde cholangiopancreatography and radiologically (percutaneous) when the endoscopic route is not feasible. Complications associated with the endoscopic placement of biliary endoprostheses are well described in the literature, with migration being the most common. Intestinal obstruction is a rare complication associated with the migration of these devices. There are no reports in the literature of this complication occurring after percutaneous placement. We present a case of a patient who arrived at the emergency department with ileal obstruction secondary to the migration and concurrent embedding of a covered stent placed radiologically to treat a biliary leak after surgery. The patient underwent diagnostic laparoscopic and ileal resection, revealing a lithiasic concretion at the tip of the stent, causing the small bowel obstruction.


Subject(s)
Foreign-Body Migration , Intestinal Obstruction , Stents , Humans , Stents/adverse effects , Intestinal Obstruction/etiology , Intestinal Obstruction/surgery , Foreign-Body Migration/surgery , Foreign-Body Migration/diagnostic imaging , Foreign-Body Migration/complications , Male , Cholangiopancreatography, Endoscopic Retrograde , Female , Aged , Laparoscopy , Intestine, Small
9.
World Neurosurg ; 184: 372-386, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38590071

ABSTRACT

Although numerous case series and meta-analyses have shown the efficacy of venous sinus stenting (VSS) in the treatment of idiopathic intracranial hypertension and idiopathic intracranial hypertension-associated pulsatile tinnitus, there remain numerous challenges to be resolved. There is no widespread agreement on candidacy; pressure gradient and failed medical treatment are common indications, but not all clinicians require medical refractoriness as a criterion. Venous manometry, venography, and cerebral angiography are essential tools for patient assessment, but again disagreements exist regarding the best, or most appropriate, diagnostic imaging choice. Challenges with the VSS technique also exist, such as stent choice and deployment. There are considerations regarding postprocedural balloon angioplasty and pharmacologic treatment, but there is insufficient evidence to formalize postoperative decision making. Although complications of VSS are relatively rare, they include in-stent stenosis, hemorrhage, and subdural hematoma, and the learning curve for VSS presents specific challenges in navigating venous anatomy, emphasizing the need for wider availability of high-quality training. Recurrence of symptoms, particularly stent-adjacent stenosis, poses challenges, and although restenting and cerebrospinal fluid-diverting procedures are options, there is a need for clearer criteria for retreatment strategies. Despite these challenges, when comparing VSS with traditional cerebrospinal fluid-diverting procedures, VSS emerges as a favorable option, with strong clinical outcomes, lower complication rates, and cost-effectiveness. Further research is necessary to refine techniques and indications and address specific aspects of VSS to overcome these challenges.


Subject(s)
Intracranial Hypertension , Pseudotumor Cerebri , Tinnitus , Humans , Pseudotumor Cerebri/complications , Pseudotumor Cerebri/diagnostic imaging , Pseudotumor Cerebri/surgery , Tinnitus/etiology , Tinnitus/surgery , Constriction, Pathologic/diagnostic imaging , Constriction, Pathologic/surgery , Constriction, Pathologic/complications , Cranial Sinuses/diagnostic imaging , Cranial Sinuses/surgery , Stents/adverse effects , Intracranial Hypertension/surgery , Intracranial Hypertension/complications , Treatment Outcome , Retrospective Studies
10.
Sci Rep ; 14(1): 8723, 2024 04 16.
Article in English | MEDLINE | ID: mdl-38622273

ABSTRACT

The Alpha stent is an intracranial closed-cell stent with a unique mesh design to enhance wall apposition. It recently underwent structural modifications to facilitate easier stent deployment. This study aimed to evaluate the safety and efficacy of stent-assisted coil embolization for unruptured intracranial aneurysms using the Alpha stent. Between January 2021 and November 2021, 35 adult patients with 35 unruptured intracranial aneurysms in the distal internal carotid artery were prospectively enrolled. For efficacy outcomes, magnetic resonance angiography at the 6-month follow-up was evaluated using the Raymond-Roy occlusion classification (RROC). The safety outcome evaluated the occurrence of symptomatic procedure-related neurological complications up to 6 months postoperatively. Technical success was achieved in 34/35 (97.1%). Six months postoperatively, aneurysm occlusion showed RROC I in 32/35 (91.4%) and RROC II in 3/35 (8.6%) patients. Procedure-related neurologic complications occurred in one patient (2.9%) who experienced hemiparesis due to acute lacunar infarction, which resulted in a 6-month mRS score of 1. The Alpha stent demonstrated excellent efficacy and safety outcomes in stent-assisted coil embolization of unruptured distal ICA aneurysms. The recent structural modifications allowed for easier stent delivery and deployment.Clinical trial registration number: KCT0005841; registration date: 28/01/2021.


Subject(s)
Embolization, Therapeutic , Intracranial Aneurysm , Adult , Humans , Intracranial Aneurysm/diagnostic imaging , Intracranial Aneurysm/surgery , Treatment Outcome , Embolization, Therapeutic/adverse effects , Embolization, Therapeutic/methods , Stents/adverse effects , Blood Vessel Prosthesis , Cerebral Angiography/methods , Retrospective Studies
11.
Bratisl Lek Listy ; 125(5): 289-298, 2024.
Article in English | MEDLINE | ID: mdl-38624053

ABSTRACT

Cardio-cerebral infarction (CCI) is a term coined to describe concomitant myocardial infarction and acute ischemic stroke. Acute myocardial infarction and stroke, as separate events, constitute some of the most important causes for disability and mortality in aging societies. Stroke can either occur simultaneously with myocardial infarction or become a serious complication of myocardial infarction and/or its treatment. The frequency of CCI has been reported at a 0.009% incidence rate in stroke patients and is associated with an extremely high mortality. Because of the rare occurrence of CCI, there are currently no guidelines for assessing its diagnosis and optimal treatment. Therefore, currently, the management of CCI cases needs to be individualized. Hopefully, in the future, the results of large clinical trials or prospective registries are expected to enhance our understanding of managing concomitant acute MI and stroke. In this review we have focused on the current literacy in the diagnosis and treatment of CCIs. The paper illustrates potential distinct scenarios of CCI through the analysis of three patient cases (Fig. 5, Ref. 65). Text in PDF www.elis.sk Keywords: myocardial infarction, stroke, cardio-cerebral infarction, carotid artery stenting, cardiac surgery.


Subject(s)
Carotid Stenosis , Ischemic Stroke , Myocardial Infarction , Stroke , Humans , Prospective Studies , Ischemic Stroke/complications , Treatment Outcome , Stents/adverse effects , Stroke/complications , Stroke/diagnosis , Myocardial Infarction/complications , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Cerebral Infarction/complications , Risk Factors
13.
Pol Przegl Chir ; 96(2): 21-25, 2024 Apr 02.
Article in English | MEDLINE | ID: mdl-38629277

ABSTRACT

<b><br>Indroduction:</b> Significant dysphagia, aspiration pneumonia, and impossible oral nutrition in patients with unresectable or recurrent gastroesophageal malignancy or bronchial cancer invading the oesophagus with a tracheoesophageal fistula lead to cachexia. Dehiscence of the esophago-jejunal or gastroesophageal anastomosis may cause severe oesophageal haemorrhage. We believe that X-ray-guided oesophageal stent implantation (SEMS) is an alternative palliative method for microjejunostomy or full parenteral nutrition.</br> <b><br>Aim:</b> The aim of this paper was to assess the safety and efficacy of a novel X-ray-guided oesophageal stent implantation technique.</br> <b><br>Materials and methods:</b> This retrospective analysis included 54 patients (35 men and 19 women) treated for malignant dysphagia, gastroesophageal/gastrointestinal anastomotic fistula or bronchoesophageal fistula in two Surgical Units between 2010 and 2019, using a modified intravascular approach to oesophageal stent implantation.</br> <b><br>Results:</b> The presented modified intravascular method of oesophageal stent implantation was successfully performed in all described patients requiring oral nutrition restoration immediately following oesophageal stent implantation. Two patients with oesophageal anastomotic dehiscence died on postoperative days 7 and 9 due to circulatory and respiratory failure. One patient was reimplanted due to a recurrent fistula. Two patients with ruptured thoracic aneurysm and thoracic stent graft implantation due to oesophageal haemorrhage, who were implanted with an oesophageal stent, died on postoperative days 4 and 14.</br> <b><br>Conclusions:</b> The modified intravascular X-ray-guided SEMS technique may be a palliative treatment for patients with unresectable oesophageal malignancies.</br>.


Subject(s)
Carcinoma , Deglutition Disorders , Esophageal Neoplasms , Tracheoesophageal Fistula , Male , Humans , Female , Deglutition Disorders/etiology , Deglutition Disorders/surgery , X-Rays , Retrospective Studies , Neoplasm Recurrence, Local , Esophageal Neoplasms/complications , Esophageal Neoplasms/surgery , Carcinoma/etiology , Stents/adverse effects , Hemorrhage/etiology
14.
Khirurgiia (Mosk) ; (4): 125-140, 2024.
Article in Russian | MEDLINE | ID: mdl-38634594

ABSTRACT

Among all patients with gastric cancer, 40% admit to the hospitals due to cancer-related complications. The most common complications of gastric cancer are bleeding (22-80%), malignant gastric outlet obstruction (26-60%), and perforation (less than 5%). The main treatment methods for gastric cancer complicated by bleeding are various forms of endoscopic hemostasis, transarterial embolization and external beam radiotherapy. Surgical treatment is possible in case of ineffective management. However, surgical algorithm is not standardized. Malignant gastric outlet stenosis requires decompression: endoscopic stenting, palliative gastroenterostomy. Surgical treatment is also possible (gastrectomy, proximal or distal resection of the stomach). The main problem for patients with complicated gastric cancer is the lack of standardized algorithms and abundance of potential surgical techniques. The aim of our review is to systematize available data on the treatment of complicated gastric cancer and to standardize existing methods.


Subject(s)
Gastric Outlet Obstruction , Pyloric Stenosis , Stomach Neoplasms , Humans , Stomach Neoplasms/surgery , Gastroenterostomy/adverse effects , Gastric Outlet Obstruction/complications , Gastric Outlet Obstruction/surgery , Pyloric Stenosis/surgery , Constriction, Pathologic/surgery , Stents/adverse effects , Palliative Care/methods
15.
PLoS One ; 19(4): e0301448, 2024.
Article in English | MEDLINE | ID: mdl-38557900

ABSTRACT

OBJECTIVE: This study aimed to analyze the effect of coronary stent policies implemented in Shanghai on the risk of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) inpatients based on real-world data. METHODS: Two retrospective cohorts of inpatients with a first diagnosis of ACS who had undergone PCI for the first time in the previous year in Shanghai hospitals were examined (one for the postpolicy period and the other for the prepolicy period). χ2 tests were used to compare categorical variables between the two cohorts. Single- and multivariate Cox proportional hazards models were used to compare the risk of major adverse cardiovascular events (MACEs) between the two cohorts. RESULTS: A total of 31,760 ACS patients were included in this study. The proportion of ACS inpatients who had at least one bid-winning stent and 3 or more coronary stents implanted for first-time PCI in the postpolicy cohort was higher than that in the prepolicy cohort (86.52% vs. 55.67% and 6.27% vs. 4.39%, respectively; all p values < 0.0001). The single- and multivariate Cox proportional hazards models revealed that the unadjusted and adjusted hazard ratios for MACEs at 1 year after PCI for the postpolicy cohort relative to the prepolicy cohort were 0.869 (P<0.0001) and 0.814 (P = 0.0007), respectively. CONCLUSIONS: The implementation of coronary stent policies changed coronary stent utilization but had no significant adverse effects on the risk of PCI among ACS patients in Shanghai in the short term. However, the reasons for changes in the number of coronary stents implanted should be analyzed and addressed in the future.


Subject(s)
Acute Coronary Syndrome , Percutaneous Coronary Intervention , Humans , Acute Coronary Syndrome/surgery , Acute Coronary Syndrome/diagnosis , Percutaneous Coronary Intervention/adverse effects , Retrospective Studies , Treatment Outcome , China/epidemiology , Stents/adverse effects , Risk Factors
16.
Medicina (Kaunas) ; 60(4)2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38674195

ABSTRACT

Despite ongoing progress in stent technology and deployment techniques, in-stent restenosis (ISR) still remains a major issue following percutaneous coronary intervention (PCI) and accounts for 10.6% of all interventions in the United States. With the continuous rise in ISR risk factors such as obesity and diabetes, along with an increase in the treatment of complex lesions with high-risk percutaneous coronary intervention (CHIP), a substantial growth in ISR burden is expected. This review aims to provide insight into the mechanisms, classification, and management of ISR, with a focus on exploring innovative approaches to tackle this complication comprehensively, along with a special section addressing the approach to complex calcified lesions.


Subject(s)
Coronary Restenosis , Percutaneous Coronary Intervention , Stents , Humans , Percutaneous Coronary Intervention/methods , Percutaneous Coronary Intervention/adverse effects , Coronary Restenosis/etiology , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/therapy , Stents/adverse effects , Risk Factors , Ultrasonography, Interventional/methods
17.
Medicina (Kaunas) ; 60(4)2024 Apr 04.
Article in English | MEDLINE | ID: mdl-38674246

ABSTRACT

Background and Objectives: Our study aimed to reveal the effect of using 4 mm bare-metal stents (BMS), 4 mm drug-eluting stents (DES), or 3 mm DES with 4 mm diameter balloon post-dilation strategies on long-term clinical outcomes and endpoints for large-diameter coronary artery percutaneous coronary intervention (PCI). Materials and Methods: In our study, patients who had undergone PCI were retrospectively screened between January 2014 and July 2020. The study included 350 patients and was divided into three groups; Group I (n = 134) included patients with direct 4.0 mm BMS implantation, Group II (n = 109) included patients with direct 4.0 DES implantation, and Group III (n = 107) included patients with 4mm NC post-dilatation after 3 mm DES implantation. Primary endpoints were determined as target lesion revascularisation, cardiac mortality, and myocardial infarction associated with the target vessel. Our secondary endpoint was all-cause mortality. Results: No differences were observed between the groups in terms of the baseline variables. Stent length was the highest in Group II and the shortest in Group III. There were no significant differences between the groups regarding major adverse cardiovascular events (MACE). Conclusions: Our study suggests that in percutaneous coronary interventions for non-complex lesions, there is no significant difference in MACE outcomes when directly implanting a 4 mm diameter DES, a 4 mm diameter BMS, or a 3 mm diameter DES, followed by post-dilation with an appropriately sized NC balloon when the target vessel diameter is in the range of 4 to 4.4 mm.


Subject(s)
Coronary Vessels , Drug-Eluting Stents , Percutaneous Coronary Intervention , Stents , Humans , Male , Female , Retrospective Studies , Percutaneous Coronary Intervention/methods , Aged , Middle Aged , Treatment Outcome , Stents/adverse effects , Stents/standards , Coronary Vessels/surgery , Coronary Artery Disease/surgery , Coronary Artery Disease/therapy
18.
World Neurosurg ; 184: 361-371, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38590070

ABSTRACT

Venous sinus stenosis has garnered increasing academic attention as a potential etiology of idiopathic intracranial hypertension (IIH) and pulsatile tinnitus (PT). The complex anatomy of the cerebral venous sinuses and veins plays a crucial role in the pathophysiology of these conditions. Venous sinus stenosis, often found in the superior sagittal or transverse sinus, can lead to elevated intracranial pressure (ICP) and characteristic IIH symptoms. Stenosis, variations in dural venous anatomy, and flow dominance patterns contribute to aberrant flow and subsequent PT. Accurate imaging plays a vital role in diagnosis, and magnetic resonance (MR) venography is particularly useful for detecting stenosis. Management strategies for IIH and PT focus on treating the underlying disease, weight management, medical interventions, and, in severe cases, surgical or endovascular procedures. Recently, venous sinus stenting has gained interest as a minimally invasive treatment option for IIH and PT. Stenting addresses venous sinus stenosis, breaking the feedback loop between elevated ICP and stenosis, thus reducing ICP and promoting cerebrospinal fluid outflow. The correction and resolution of flow aberrances can also mitigate or resolve PT symptoms. While venous sinus stenting remains an emerging field, initial results are promising. Further research is needed to refine patient selection criteria and evaluate the long-term efficacy of stenting as compared to traditional treatments.


Subject(s)
Intracranial Hypertension , Pseudotumor Cerebri , Tinnitus , Humans , Pseudotumor Cerebri/complications , Pseudotumor Cerebri/diagnosis , Pseudotumor Cerebri/surgery , Tinnitus/diagnosis , Tinnitus/etiology , Tinnitus/therapy , Constriction, Pathologic/complications , Constriction, Pathologic/diagnostic imaging , Constriction, Pathologic/surgery , Intracranial Hypertension/complications , Intracranial Hypertension/diagnosis , Cranial Sinuses/diagnostic imaging , Cranial Sinuses/surgery , Stents/adverse effects
20.
Sci Rep ; 14(1): 7669, 2024 04 01.
Article in English | MEDLINE | ID: mdl-38561485

ABSTRACT

A tapered stent with inclined proximal end is designed for fitting the iliac anatomically. The aim of the present study was to evaluate the safety and performance of the new stent in ovine left iliac veins. The experiment was performed in 30 adult sheep, and one nitinol-based VENA-BT® iliac venous stent (KYD stent) was implanted into each animal's left common iliac vein. Follow-up in all sheep consisted of angiographic, macroscopic, and microscopic examinations at Day 0 (< 24 h), Day 30, Day 90, Day 180 and Day 360 post-stenting (six animals per each time-point). 30 healthy ~ 50 kg sheep were included in this study and randomly divided into five groups according to the follow-up timepoint. All stents were implanted successfully into the left ovine common iliac vein. No significant migration occurred at follow-up. There is no statistically significant difference between the groups (p > 0.05), indicating no serious lumen loss occurred during the follow-up period. Common iliac venous pressure was further measured and the results further indicated the lumen patency at follow-up. Histological examinations indicated that no vessel injury and wall rupture, stent damage, and luminal thrombus occurred. There was moderate inflammatory cell infiltration around the stent in Day-0 and Day-30 groups with the average inflammation score of 2.278 and 2.167, respectively. The inflammatory reaction was significantly reduced in Day-90, Day-180 and Day-360 groups and the average inflammation scores were 0.9444 (p < 0.001, Day-90 vs Day-0), 1.167 (p < 0.001, Day-180 vs Day-0) and 0.667 (p < 0.001, Day-90 vs Day-0), respectively. The microscopic examinations found that the stents were well covered by endothelial cells in all follow-up time points. The results suggested that the KYD stent is feasible and safe in animal model. Future clinical studies may be required to further evaluate its safety and efficacy.


Subject(s)
Alloys , Endothelial Cells , Iliac Vein , Animals , Iliac Vein/diagnostic imaging , Iliac Vein/surgery , Inflammation , Retrospective Studies , Sheep , Stents/adverse effects , Treatment Outcome , Vascular Patency
SELECTION OF CITATIONS
SEARCH DETAIL
...